) recently presented positive results on oncology drug Jakavi
from a three-year follow up analysis of a phase III trial,
It was observed that the overall survival rate improved
significantly in patients treated with Jakavi along with
sustained reductions in spleen size versus patients treated with
Additionally, the study showed that Jakavi slowed and stabilized
the progress of bone marrow fibrosis. Moreover, Novartis observed
a 52% reduction in the risk of death in patients treated with
The results were in line with the previous studies and reinstated
that Jakavi is more effective than conventional therapy for
patients, who suffer from myelofibrosis.
We note that Jakavi was approved in the EU in 2012 for the
treatment of disease-related splenomegaly or symptoms in adult
patients with primary myelofibrosis, post-polycythemia vera
myelofibrosis or post-essential thrombocythemia myelofibrosis.
Jakavi was granted "orphan drug" status in the US and Europe.
Novartis has a licensing agreement with
) for the development and commercialization of Jakavi outside the
Jakavi was approved in the US in Nov 2011 where it is available
under the trade name, Jakafi. Incyte markets Jakafi in the US for
the treatment of patients with intermediate or high-risk
Novartis generated $30 million of revenues from the sales of
Jakavi in 2012. It is approved in 45 countries as of now with
additional worldwide regulatory filings are underway.
Positive results from the study should boost the sales potential
of the drug. We are encouraged by the recent bout of positive
results at Novartis. Novartis recently released encouraging data
on diabetes drug Galvus as well.
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
) look well placed with a Zacks Rank #2 (Buy).
CUBIST PHARM (CBST): Free Stock Analysis
INCYTE CORP (INCY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.